Why Evolus Stock Soared Today

Demand for Evolus' beauty products is growing. Management expects to generate sustainable profits in 2026.

The Motley Fool • Mar 5, 2026

Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript

Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 4, 2026

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the fourth quarter and full-year ended December 31, 2025. “In 2025 we generated nearly $300 million in total net revenue delivering our sixth consecutive year of double-digit growth,” said David Moatazedi, President and Chief Executive Officer of Evolus. “Our performance beauty posit.

Business Wire • Mar 3, 2026

Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates

Evolus, Inc. (EOLS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.01 per share a year ago.

Zacks Investment Research • Mar 4, 2026

Evolus to Participate in The Leerink Partners Global Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL. The fireside chat will take place on Wednesday, March 11, 2026, at 11:20 AM ET. The fireside chat can be accessed on the Investor Relations page of the.

Business Wire • Feb 25, 2026

Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 24, 2026

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's.

Business Wire • Feb 17, 2026

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today reported the grant during December 2025, January 2026, and February 2026 of an aggregate of 153,218 restricted stock units (RSUs) and 34,952 stock options of the company's common stock to 36 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under.

Business Wire • Feb 13, 2026

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2025. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company's 2025 financial results is completed a.

Business Wire • Jan 9, 2026

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materially decreased our position as we evaluate this specific risk.

Seeking Alpha • Dec 15, 2025